PER ASX · Health Care

Percheron Therapeutics Ltd

Announcements, last 12 months: 78
Price sensitive, last 12 months: 15
Followed on InvestorPA: Low (Outside the 20% most-followed companies on InvestorPA)

Latest announcements

Released	Headline	Actions
23 Oct 2026, 9:46 AM	Completion of HMBD-002 Drug Product Manufacture
20 Oct 2026, 11:15 AM	Quarterly Activities Report and Appendix 4C Price sensitive
20 Oct 2026, 8:42 AM	Photosoft and Novel Immunotherapy Collaboration Partnership
20 Oct 2026, 8:23 AM	Percheron and Invion to Explore Cancer Combination Therapy
15 Oct 2026, 9:36 AM	Change of Director's Interest Notice
15 Oct 2026, 8:17 AM	Notice under S708A
14 Oct 2026, 9:29 AM	Application for quotation of securities - PER
14 Oct 2026, 9:20 AM	Application for quotation of securities - PER
8 Oct 2026, 1:12 PM	Change of Director's Interest Notice
8 Oct 2026, 1:09 PM	Notification regarding unquoted securities - PER

Sign in to see all PER announcements.

Guidance history

28 Aug 2026	No specific financial guidance provided in the announcement.
19 Aug 2026	Percheron Therapeutics Ltd reported a loss of $4,791,745 for the year ended 30 June 2026.
19 Aug 2026	Percheron expects to commence a phase II clinical trial of HMBD-002 in the second half of CY2026.

Sign in to see the full guidance history.

Most followed in Health Care

PME Pro Medicus Ltd
AHC Austco Healthcare Ltd
CSL CSL Ltd
RMD Resmed Inc
TLX TELIX Pharmaceuticals Ltd
CGS Cogstate Ltd
ALC Alcidion Group Ltd
CSX Cleanspace Holdings Ltd

Follow PER to get its announcements emailed to you, with AI summaries, the full announcement and guidance history, and its most significant announcements.